ANP_PHARMA_LTD - Accounts

Company Registration No. 06111337 (England and Wales)
ANP PHARMA LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2022
PAGES FOR FILING WITH REGISTRAR
ANP PHARMA LTD
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 7
ANP PHARMA LTD
BALANCE SHEET
AS AT
31 MARCH 2022
31 March 2022
- 1 -
2022
2021
Notes
£
£
£
£
Fixed assets
Tangible assets
3
269,893
111,291
Current assets
Stocks
180,015
137,934
Debtors
4
1,151,125
1,033,682
Cash at bank and in hand
915,244
745,046
2,246,384
1,916,662
Creditors: amounts falling due within one year
5
(1,175,110)
(913,313)
Net current assets
1,071,274
1,003,349
Total assets less current liabilities
1,341,167
1,114,640
Creditors: amounts falling due after more than one year
6
(86,685)
-
0
Provisions for liabilities
7
(32,728)
(10,815)
Net assets
1,221,754
1,103,825
Capital and reserves
Called up share capital
10
100
100
Profit and loss reserves
1,221,654
1,103,725
Total equity
1,221,754
1,103,825

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 March 2022 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

ANP PHARMA LTD
BALANCE SHEET (CONTINUED)
AS AT
31 MARCH 2022
31 March 2022
- 2 -
The financial statements were approved by the board of directors and authorised for issue on 7 March 2023 and are signed on its behalf by:
A Patel
Director
Company Registration No. 06111337
ANP PHARMA LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2022
- 3 -
1
Accounting policies
Company information

ANP Pharma Ltd is a private company limited by shares incorporated in England and Wales. The registered office is Unit 9 Honywood Business Park, Honywood Road, Basildon, Essex, England, SS14 3HW.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods provided in the normal course of business, and is shown net of VAT. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

1.3
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold improvements
Over the term of lease
Fixtures, fittings & equipment
25% reducing balance method
Motor vehicles
25% reducing balance method

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.4
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

1.5
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises of direct materials only.

ANP PHARMA LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2022
1
Accounting policies
(Continued)
- 4 -

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.6
Cash and cash equivalents

Cash at bank and in hand are basic financial assets and include cash in hand and deposits held at call with banks.

1.7
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including trade creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.8
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs.

1.9
Taxation

The tax expense represents the sum of the tax currently payable.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

ANP PHARMA LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2022
1
Accounting policies
(Continued)
- 5 -
Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

1.10
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

1.11
Retirement benefits

The company operates a defined contribution scheme for the benefit of its employees. Contributions payable are charged to the profit and loss account in the year they are payable.

1.12
Leases

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessees. All other leases are classified as operating leases.

 

Assets held under finance leases are recognised as assets at the lower of the assets fair value at the date of inception and the present value of the minimum lease payments. The related liability is included in the balance sheet as a finance lease obligation. Lease payments are treated as consisting of capital and interest elements. The interest is charged to profit or loss so as to produce a constant periodic rate of interest on the remaining balance of the liability.

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

1.13
Government grants

Government grants, which include amounts received under the Coronavirus Job Retention Scheme, are recognised at the fair value of the grant receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received. The income is recognised in other income on a systematic basis over the periods in which the associated costs are incurred, using the accrual model.

1.14
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2022
2021
Number
Number
Total
9
9
ANP PHARMA LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2022
- 6 -
3
Tangible fixed assets
Leasehold improvements
Fixtures, fittings & equipment
Motor vehicles
Total
£
£
£
£
Cost
At 1 April 2021
55,401
164,688
-
0
220,089
Additions
-
0
16,515
221,380
237,895
At 31 March 2022
55,401
181,203
221,380
457,984
Depreciation and impairment
At 1 April 2021
8,617
100,181
-
0
108,798
Depreciation charged in the year
3,693
20,255
55,345
79,293
At 31 March 2022
12,310
120,436
55,345
188,091
Carrying amount
At 31 March 2022
43,091
60,767
166,035
269,893
At 31 March 2021
46,784
64,507
-
0
111,291
4
Debtors
2022
2021
Amounts falling due within one year:
£
£
Trade debtors
859,712
879,450
Other debtors
214,839
139,593
Prepayments and accrued income
76,574
14,639
1,151,125
1,033,682

Included in other debtors is a sum of £336 (2021: £20,757) owed by the directors of the company. This balance was repaid post year end.

5
Creditors: amounts falling due within one year
2022
2021
£
£
Obligations under finance leases
17,285
-
0
Trade creditors
827,971
666,903
Corporation tax
28,083
75,406
Other creditors
286,582
155,964
Accruals and deferred income
15,189
15,040
1,175,110
913,313
ANP PHARMA LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2022
- 7 -
6
Creditors: amounts falling due after more than one year
2022
2021
Notes
£
£
Obligations under finance leases
86,685
-
0
7
Provisions for liabilities
2022
2021
£
£
Deferred tax liabilities
32,728
10,815
8
Operating lease commitments
Lessee

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2022
2021
£
£
443,333
481,333
9
Financial commitments, guarantees and contingent liabilities

The company has given a fixed and floating charge over the company’s assets to Lloyds Bank PLC, who have given a mortgage to ANP Property Investments Ltd for the purchase of a property. The directors A and D Patel are the directors and shareholders of ANP Property Investments Ltd.

10
Called up share capital
2022
2021
2022
2021
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary A shares of £1 each
75
75
75
75
Ordinary B shares of £1 each
25
25
25
25
100
100
100
100
2022-03-312021-04-01false13 March 2023CCH SoftwareCCH Accounts Production 2022.300No description of principal activityC CurranA PatelD R PatelS Patel061113372021-04-012022-03-31061113372022-03-31061113372021-03-3106111337core:LeaseholdImprovements2022-03-3106111337core:FurnitureFittings2022-03-3106111337core:MotorVehicles2022-03-3106111337core:LeaseholdImprovements2021-03-3106111337core:FurnitureFittings2021-03-3106111337core:MotorVehicles2021-03-3106111337core:CurrentFinancialInstrumentscore:WithinOneYear2022-03-3106111337core:CurrentFinancialInstrumentscore:WithinOneYear2021-03-3106111337core:Non-currentFinancialInstrumentscore:AfterOneYear2022-03-3106111337core:Non-currentFinancialInstrumentscore:AfterOneYear2021-03-3106111337core:CurrentFinancialInstruments2022-03-3106111337core:CurrentFinancialInstruments2021-03-3106111337core:ShareCapital2022-03-3106111337core:ShareCapital2021-03-3106111337core:RetainedEarningsAccumulatedLosses2022-03-3106111337core:RetainedEarningsAccumulatedLosses2021-03-3106111337core:ShareCapitalOrdinaryShares2022-03-3106111337core:ShareCapitalOrdinaryShares2021-03-3106111337bus:Director22021-04-012022-03-3106111337core:FurnitureFittings2021-04-012022-03-3106111337core:MotorVehicles2021-04-012022-03-31061113372020-04-012021-03-3106111337core:LeaseholdImprovements2021-03-3106111337core:FurnitureFittings2021-03-3106111337core:MotorVehicles2021-03-31061113372021-03-3106111337core:LeaseholdImprovements2021-04-012022-03-3106111337core:Non-currentFinancialInstruments2022-03-3106111337core:Non-currentFinancialInstruments2021-03-3106111337bus:PrivateLimitedCompanyLtd2021-04-012022-03-3106111337bus:SmallCompaniesRegimeForAccounts2021-04-012022-03-3106111337bus:FRS1022021-04-012022-03-3106111337bus:AuditExemptWithAccountantsReport2021-04-012022-03-3106111337bus:Director12021-04-012022-03-3106111337bus:Director32021-04-012022-03-3106111337bus:CompanySecretary12021-04-012022-03-3106111337bus:FullAccounts2021-04-012022-03-31xbrli:purexbrli:sharesiso4217:GBP